These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35816053)

  • 1. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants following CoronaVac or ChAdOx1 nCoV-19 primary series.
    Angkasekwinai N; Niyomnaitham S; Sewatanon J; Phumiamorn S; Sukapirom K; Senawong S; Toh ZQ; Umrod P; Somporn T; Chumpol S; Ritthitham K; Jantraphakorn Y; Srisutthisamphan K; Chokephaibulkit K
    Asian Pac J Allergy Immunol; 2024 Sep; 42(3):276-289. PubMed ID: 37466962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
    Shaw RH; Liu X; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dejnirattisai W; Dinesh T; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Morey ER; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet Respir Med; 2022 Nov; 10(11):1049-1060. PubMed ID: 35690076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
    Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
    Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.
    Sudjaritruk T; Mueangmo O; Saheng J; Winichakoon P; Salee P; Wongjak W; Chaito T; Praparattanapan J; Nuket K; Solai N; Wipasa J; Chawansuntati K; Chaiwarith R
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
    Wittawatmongkol O; Bunjoungmanee P; Kosalaraksa P; Laoprasopwattana K; Boonsathorn S; Chantasrisawad N; Sudjaritruk T; Niyomnaitham S; Senawong S; Srisutthisamphan K; Quan Toh Z; Rungmaitree S; Nanthapisal S; Phanthanawiboon S; Khantee P; Techasaensiri C; Hirankarn N; Pangprasertkul S; Chokephaibulkit K
    Vaccine; 2023 Sep; 41(40):5834-5840. PubMed ID: 37586956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
    Costa Clemens SA; Marchevsky N; Kelly S; Felle S; Eldawi A; Rajasingam R; Mahmud R; Lambe T; Voysey M; Gonzalez I; Milan EP; Justino MC; Bibi S; Aley P; Clemens R; Pollard AJ
    Hum Vaccin Immunother; 2023 Aug; 19(2):2233400. PubMed ID: 37438960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
    Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
    J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
    Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.
    Suntronwong N; Kanokudom S; Auphimai C; Assawakosri S; Thongmee T; Vichaiwattana P; Duangchinda T; Chantima W; Pakchotanon P; Chansaenroj J; Puenpa J; Nilyanimit P; Srimuan D; Thatsanatorn T; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Poovorawan Y
    J Med Virol; 2022 Dec; 94(12):5713-5722. PubMed ID: 35924475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.
    Chuang CH; Huang CG; Huang CT; Chen YC; Kung YA; Chen CJ; Chuang TC; Liu CC; Huang PW; Yang SL; Gu PW; Shih SR; Chiu CH
    J Clin Virol; 2022 Dec; 157():105328. PubMed ID: 36399969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study.
    Kohmer N; Stein S; Schenk B; Grikscheit K; Metzler M; Rabenau HF; Widera M; Herrmann E; Wicker S; Ciesek S
    Int J Infect Dis; 2023 Mar; 128():166-175. PubMed ID: 36587839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.